Manager, Cell Line & Media Development
Joining the Sartorius Stedim Cellca team in December 2018, Bernd brings over 25 years in the cell line development field within the biotech industry. Over the years, Bernd has worked on developing GMP-compliant processes for clinical grade rAAV production, heading the cell line development team at Rentschler, leading projects to generate & characterize cell line for GMP production, and most recently director of process development for gene therapy.
Dr Carron Nairn
Director of Technical Development, Biosafety
Carron joined as a founding member of BioOutsource and comes with a wealth of experience in contract testing from BioReliance (formerly Q-One Biotech). She holds a BSc (Hons) in Applied Biology, and during a 10 year career in academic research gained a MSc in Ovarian Cancer Research and a PhD in Molecular Virology studying Enteroviruses and their relationship to chronic diseases. Carron initially focused on establishing the Molecular Services group at BioOutsource, designing and validating a wide range of real time PCR assays for the detection of adventitious agents. This role expanded quickly to encompass the in-vitro service offering and today she leads a team of experienced scientists specializing in the safety testing and characterization of viral vaccines and cell banks.
Dr Catriona Thomson
Director - R&D and Technical Services
Catriona joined Sartorius Stedim BioOutsource in 2008 after completing a MSc (Hons) in Plant Science and a PhD in Biochemistry and Molecular Biology at the University of Glasgow, and quickly became a key member of the bioanalytical team. She developed expertise in the development, qualification and validation of ELISAs and bioassays under GxP regulations and has a particular interest in the mechanisms of action of monoclonal antibodies. She progressed to the role of Associate Director of Bioanalytical Technical Services, and is now Director of R&D and Technical Services after playing a pivotal role in the development of BioOutsource’s biosimilar characterization and comparability packages. As well as becoming a technical champion for our bioanalytical services.
Dr Jennifer Lawson
Director - Bioanalytical Services
Jennifer joined Sartorius Stedim BioOutsource in 2012 from a preclinical testing CRO where she was the Operations Manager. Prior to this, Jennifer completed her PhD in Immunology at King’s College London and spent several years in academic research. Jennifer initially joined BioOutsource as the Head of R&D, where she developed the first biosimilar service offerings. Jennifer built up the biosimilars operations team from its inception to the present day, allowing BioOutsource to offer clients dedicated, expert teams with a wealth of experience to support their biosimilar programs.
Dr Shona Campbell
Director - Bioanalytical Services
Shona joined BioOutsource in 2010 after completing a Post Doctoral position at the University of Bristol. Shona has a BSc (Hons) in Plant Science and a PhD in Cell Wall Biochemistry and quickly became a key member of the bioanalytical team. Working in the bioanalytical department for the past 5 years, Shona has developed a wide range of experience in performing cell-based assays as well as assay development, qualification and validation, under GXP regulations and utilizing platforms such as ELISA, MSD and cell-based assays. She now leads a dedicated team of senior scientists, scientists and analysts performing analytical testing for our clients’ drug candidates.
Dr Sarah Stone
Bioanalytical - Biacore
Dr. Sarah Stone joined Sartorius Stedim BioOutsource Ltd in 2012, following a successful academic career, and quickly became a key member of the biosimilars department. During a period of rapid growth for the company, Sarah developed expertise in the characterization of biosimilar monoclonal antibody-based therapies for some of the blockbuster molecules, including Rituximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab; using SPR-based technologies, namely the Biacore T200 and Biacore 4000 systems.
Currently, Sarah leads the Biacore department at BioOutsource, working on a wide range of commercial and R&D projects to develop a range of new Biacore assays. Although initially focussed on characterization of Fc binding characteristics, the work of the department has increasingly started to focus on the challenges of analysing the high affinity Fab-antigen interaction which can be particularly problematic for receptor-Fc fusion proteins and affinity matured molecules.
Dr Martin De Cecco
Biochemistry - R&D
Martin joined Sartorius Stedim BioOutsource as a Senior Scientist in 2015. Previously, Martin spent 5 years developing applications for biopharmaceutical analysis at a leading LC/MS vendor. He gained his PhD in 2011 from the University of Edinburgh, where he used mass spectrometry to investigate structure-function relationships of antimicrobial peptides. In his current role at BioOutsource, he leads the development of new physicochemical methods for the structural characterization of monoclonal antibodies.
Dr Graeme Anderson
Graeme joined Sartorius Stedim BioOutsource in 2016 and has spent many years within the biopharmaceutical industry, gaining a broad depth of knowledge of lot release testing, stability and routine testing of client materials within CROs. Graeme completed a PhD in Pharmaceutical Chemistry at the School of Pharmacy, University of London and spent several years lecturing and in academic research. Experienced in the purification, structural analysis and physicochemical characterization of peptides and proteins, he is the Senior Scientist within the Biochemistry group, focusing on physicochemical testing of client biosimilar and related molecules.
Scientist - Biosafety
Kirsty joined BioOutsource in 2008 after completing a First Class BSc (Hons) in Genetics at the University of Glasgow. She initially worked as an Analyst in the biosafety team where she gained a wide range of experience in cell based and molecular assays, before her dedication and enthusiasm resulted in her progressing to the position of Scientist within the biosafety team in 2011. In this role, Kirsty is responsible for ensuring the technical excellence of the work performed by the team as well as maintaining effective communication with BioOutsource’s clients.
Sajida joined BioOutsource in 2011 following a successful ten year career at Lamellar Biomedical Ltd specializing in TEM and SEM. She was initially responsible for setting up the TEM facility at BioOutsource and developing and validating the different methodologies. The introduction enabled BioOutsource to provide a complete testing package for the detection of adventitious agents for cell banks, virus banks and bulk harvest materials under cGMP regulations. She is a Senior Scientist in the biosafety department and manages our subcontract testing programme in addition to providing TEM services to clients. Sajida also holds a B.Sc. (Hons) in Microbiology from University of Glasgow and a Medical degree (MBBS) from Pakistan.
Production Manager Cell Bank Manufacturing
Andrew has 12 years cGMP experience in contract and commercial manufacturing environments, specialising in cGMP contract manufacturing of mammalian cell banks, viral manufacturing and commercial upstream process for Japanese Encephalitis Vaccine. Experienced in sterile glass vial fill/finish of early phase clinical trial material. Previously held Production / Team Leader positions at BioReliance, Valneva (formally Intercell) and Symbiosis Pharma
Gi Yin Tang
Scientist - Biosafety
Gi Yin holds a BSc (Hons) in Virology and joined BioOutsource as an analyst in 2008, where she gained a wide range of experience in molecular, analytical and cell-based assays. She progressed to a Scientist position in the department with a focus on molecular assays such as Identity Testing, Mycoplasma by PCR, and PCR screening assays.